Laboratoires Thea
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING3
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Kinezodianone R hydrochloride NCT05389267 |
P1/2 | Active, not recruiting | Glaucoma; Ocular Hypertension | 120 | 2024-12-31 |
| Slit Lamp Examination NCT07169695 |
P2 | Recruiting | Moderate to Severe Vernal Keratoconjunctivitis | 120 | 2027-01-21 |
| HYPERION NCT06891443 |
P3 | Recruiting | Leber Congenital Amaurosis 10; Blindness | 32 | 2027-11 |
| T10430 lower dose NCT07522242 |
P2 | Recruiting | Myopia | 200 | 2027-11 |
| LUNA NCT06627179 |
P2 | Active, not recruiting | Retinitis Pigmentosa (RP); Usher Syndrome Type 2 | 81 | 2028-07 (+7 mo) |
| CAPELLA NCT07796646 |
P2 | Not yet recruiting | Retinitis Pigmentosa (RP); Usher Syndrome Type 2 | 81 | 2030-02-28 |